Skip to main content
NVDA+0.10%AAPL-0.10%GOOGL-1.24%MSFT0.00%AMZN+0.25%TSM+1.49%SPCX+1.89%META-0.36%AVGO-0.48%TSLA-0.14%LLY-2.54%BRK-B-0.87%MU+0.09%SKHY+4.05%WMT-1.02%JPM-1.47%AMD+1.74%V-1.55%XOM+2.79%JNJ-1.42%ASMLa-0.87%MA-1.52%ABBV+0.16%CVX+2.88%INTC+1.72%0700.HK+0.94%COST-1.46%1398.HK-1.50%CSCO+1.53%KO-2.76%ORCL+0.49%UNH-1.62%PG-2.76%BAC-1.02%1816.HK+0.44%3988.HK-0.50%HD-2.41%CAT-2.42%0005.HK-1.04%PM-1.13%HSBA.L-1.07%AP2d-0.03%0857.HK-0.93%0939.HK+0.51%AMAT+0.44%GE-2.69%1288.HK-1.94%DELL+0.77%LRCX-0.02%NVS-3.30%GBPTRY+0.41%GBPHKD+0.32%USDMXN+0.29%GBPMXN-0.28%NZDMXN+0.27%USDILS+0.16%AUDNOK-0.14%EURCAD+0.14%USDTRY+0.13%EURJPY+0.12%SGDJPY+0.11%USDCAD+0.10%AUDSGD-0.10%EURAUD+0.10%NZDCAD+0.09%CADCHF-0.09%CHFJPY+0.08%USDJPY+0.08%NZDJPY+0.08%EURGBP+0.08%AUDNZD-0.07%AUDUSD-0.07%GBPCHF-0.05%GBPUSD-0.04%AUDCHF-0.04%GBPCAD+0.04%USDCOP-0.04%GBPNZD-0.04%EURCNH+0.03%USDDKK-0.03%GBPJPY+0.03%EURSGD+0.03%AUDCAD+0.03%USDCNH+0.03%EURUSD+0.03%GBPSGD-0.03%EURCHF+0.02%GBPAUD+0.02%NZDSGD-0.02%USDZAR+0.02%USDTHB-0.02%AUDJPY+0.02%EURNZD+0.01%NZDCHF+0.01%USDHKD+0.01%USDCHF+0.01%USDSGD-0.01%CHFSGD-0.01%CADJPY0.00%NZDUSD0.00%USDPLN0.00%USDSEK0.00%NOKJPY0.00%EURHKD0.00%EURCZK0.00%EURNOK0.00%EURZAR0.00%GBPZAR0.00%AUDDKK0.00%CHFSEK0.00%EURSEK0.00%EURDKK0.00%CHFNOK0.00%USDNOK0.00%EURPLN0.00%PLNJPY0.00%XNGUSD-1.36%USOIL-1.21%XPTUSD+0.51%XAGUSD+0.31%GAGUSD+0.31%XAUUSD+0.13%GAUUSD+0.13%HG1-0.05%S10.00%SUGAR0.00%COTTON0.00%COFFEE0.00%BTCUSD-0.48%ETHUSD+22.11%USDTUSD+0.01%XRPUSD+15.55%SOLUSD+15.78%TRXUSDT+0.49%ZECUSDT+0.84%DOGEUSD+20.76%XMRUSDT-3.54%LINKUSD+23.15%BCHUSDT+0.52%XLMUSD-1.69%UNIUSD+1.61%LTCUSD+17.32%SUIUSD-1.71%HBARUSDT-0.24%TONUSD+36.45%TAOUSDT+0.91%AAVEUSD-0.77%DOTUSDT-1.53%ICPUSDT-1.37%ONDOUSDT-0.06%WLDUSDT-3.53%ARBUSDT+0.12%JUPUSDT-1.94%ATOMUSDT+0.54%INJUSDT+2.13%STXUSDT-0.10%TIAUSDT-0.37%PYTHUSDT+5.58%FETUSDT-1.55%SEIUSDT-3.15%IMXUSDT-1.05%GRTUSDT-1.82%OPUSDT-1.73%IOTAUSDT-2.14%WIFUSDT-3.03%POLUSDT-0.09%AXSUSDT-2.01%EOSUSDT-3.88%FARTCOINUSDT-2.58%DYDXUSDT-3.00%GALAUSDT-2.36%ORDIUSDT-1.67%RONINUSDT-1.68%NOTUSDT-2.67%NVDA+0.10%AAPL-0.10%GOOGL-1.24%MSFT0.00%AMZN+0.25%TSM+1.49%SPCX+1.89%META-0.36%AVGO-0.48%TSLA-0.14%LLY-2.54%BRK-B-0.87%MU+0.09%SKHY+4.05%WMT-1.02%JPM-1.47%AMD+1.74%V-1.55%XOM+2.79%JNJ-1.42%ASMLa-0.87%MA-1.52%ABBV+0.16%CVX+2.88%INTC+1.72%0700.HK+0.94%COST-1.46%1398.HK-1.50%CSCO+1.53%KO-2.76%ORCL+0.49%UNH-1.62%PG-2.76%BAC-1.02%1816.HK+0.44%3988.HK-0.50%HD-2.41%CAT-2.42%0005.HK-1.04%PM-1.13%HSBA.L-1.07%AP2d-0.03%0857.HK-0.93%0939.HK+0.51%AMAT+0.44%GE-2.69%1288.HK-1.94%DELL+0.77%LRCX-0.02%NVS-3.30%GBPTRY+0.41%GBPHKD+0.32%USDMXN+0.29%GBPMXN-0.28%NZDMXN+0.27%USDILS+0.16%AUDNOK-0.14%EURCAD+0.14%USDTRY+0.13%EURJPY+0.12%SGDJPY+0.11%USDCAD+0.10%AUDSGD-0.10%EURAUD+0.10%NZDCAD+0.09%CADCHF-0.09%CHFJPY+0.08%USDJPY+0.08%NZDJPY+0.08%EURGBP+0.08%AUDNZD-0.07%AUDUSD-0.07%GBPCHF-0.05%GBPUSD-0.04%AUDCHF-0.04%GBPCAD+0.04%USDCOP-0.04%GBPNZD-0.04%EURCNH+0.03%USDDKK-0.03%GBPJPY+0.03%EURSGD+0.03%AUDCAD+0.03%USDCNH+0.03%EURUSD+0.03%GBPSGD-0.03%EURCHF+0.02%GBPAUD+0.02%NZDSGD-0.02%USDZAR+0.02%USDTHB-0.02%AUDJPY+0.02%EURNZD+0.01%NZDCHF+0.01%USDHKD+0.01%USDCHF+0.01%USDSGD-0.01%CHFSGD-0.01%CADJPY0.00%NZDUSD0.00%USDPLN0.00%USDSEK0.00%NOKJPY0.00%EURHKD0.00%EURCZK0.00%EURNOK0.00%EURZAR0.00%GBPZAR0.00%AUDDKK0.00%CHFSEK0.00%EURSEK0.00%EURDKK0.00%CHFNOK0.00%USDNOK0.00%EURPLN0.00%PLNJPY0.00%XNGUSD-1.36%USOIL-1.21%XPTUSD+0.51%XAGUSD+0.31%GAGUSD+0.31%XAUUSD+0.13%GAUUSD+0.13%HG1-0.05%S10.00%SUGAR0.00%COTTON0.00%COFFEE0.00%BTCUSD-0.48%ETHUSD+22.11%USDTUSD+0.01%XRPUSD+15.55%SOLUSD+15.78%TRXUSDT+0.49%ZECUSDT+0.84%DOGEUSD+20.76%XMRUSDT-3.54%LINKUSD+23.15%BCHUSDT+0.52%XLMUSD-1.69%UNIUSD+1.61%LTCUSD+17.32%SUIUSD-1.71%HBARUSDT-0.24%TONUSD+36.45%TAOUSDT+0.91%AAVEUSD-0.77%DOTUSDT-1.53%ICPUSDT-1.37%ONDOUSDT-0.06%WLDUSDT-3.53%ARBUSDT+0.12%JUPUSDT-1.94%ATOMUSDT+0.54%INJUSDT+2.13%STXUSDT-0.10%TIAUSDT-0.37%PYTHUSDT+5.58%FETUSDT-1.55%SEIUSDT-3.15%IMXUSDT-1.05%GRTUSDT-1.82%OPUSDT-1.73%IOTAUSDT-2.14%WIFUSDT-3.03%POLUSDT-0.09%AXSUSDT-2.01%EOSUSDT-3.88%FARTCOINUSDT-2.58%DYDXUSDT-3.00%GALAUSDT-2.36%ORDIUSDT-1.67%RONINUSDT-1.68%NOTUSDT-2.67%
AP

Agios Pharmaceuticals, Inc. (AGIO)

NASDAQ • Healthcare

$37
-$0.18 (-0.5%)
Market closed

Last close at October 23, 2026 at 20:00 UTC

Open$36.93
Day Range$36.1 - $37.32
Avg. Volume (3M)1.2M
Market Cap$2.2B
52 Week Range
$22.24$46
Next EarningsIn 11 daysNov 5, 2026

Metrics Over Time

Where the Money Goes

Q2 2026
Revenueeverything earned$44.7M100%
Gross Profitminus cost of goods$41.7M93%

Fundamentals & Financials

Revenue (TTM)
$98.3M
Net Income (TTM)
-$411.2M
EPS (TTM)
-$7.01
ROA (TTM)
-37.11%
Current Ratio
10.22

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Earnings

+6.1%Q1 2026-$1.85
+6.6%Q2 2026-$1.69
-2.4%Q3 2026-$1.69
Next

Nov 5

in 11 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Next report — what to expect

Agios Pharmaceuticals, Inc. (AGIO) is set to report earnings on October 29, 2026. With consensus figures not provided here, traders may focus on the company’s recent pattern: AGIO has beaten EPS in 5 of its 8 most recent quarters, making the report a key check-in on repeatability versus variability.

View full earnings history

About Agios Pharmaceuticals, Inc.

Agios Pharmaceuticals, Inc. is a NASDAQ-listed biotechnology company focused on medicines and research programs that target cellular metabolism, with work centered on hemolytic anemias and related diseases. In FY2025, the company generated $54.0 million in revenue, with its business anchored by a commercial rare-disease medicine and an earlier-stage pipeline candidate.

Name
Agios Pharmaceuticals, Inc.
CEO
Brian Goff
Website
www.agios.com
Industry
Healthcare
Year Founded
2007
Employees
540

Today's Snapshot

AI-generated

The day ended with AGIO 0.5% lower at 37.00, in line with a weaker sector. Earnings are due from AGIO on 5 November.

Trading Volume

Below 10d avg (1.2M)

920K

vs S&P 500 Today

Inline with Market

+0.01%

Updated: October 23, 2026 at 20:21 UTC

Technical Indicators

6 Buy1 Neutral1 Sell
AGIO’s technicals lean bullish as price is above short- and longer-term moving averages and momentum measures—including MACD and CCI—are positive, supported by strong on-balance volume. RSI is elevated and money flow reads strong, indicating buying interest, while ATR points to moderate volatility. However, extreme readings on the stochastic and Williams %R suggest near-term overbought conditions that could invite consolidation. Overall posture remains constructive given the breadth of moving-average support. Technical takeaway: Buy — momentum and volume underpin a bullish bias despite short-term overbought signals.
All signals
  • EMA (5 indicators)$32.18 - $34.86
    Buy
  • RSI (14)66.46
    Neutral
  • Stochastic %K (14, 3, 3)92.95
    Sell
  • MACD Level (12, 26)0.85
    Buy

Peers & Related Assets

MIRMMirum Pharmaceuticals, Inc.
$80.39-3.3%
PTCTPTC Therapeutics, Inc.
$60.59-3.9%
IRONDisc Medicine, Inc.
$74.51-0.7%
BCRXBioCryst Pharmaceuticals, Inc.
$7.65-1.7%
RAREUltragenyx Pharmaceutical Inc.
$15.65-1.9%
PHARPharming Group N.V.
Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.